Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Ofner, D; Devries, AF; Schaberl-Moser, R; Greil, R; Rabl, H; Tschmelitsch, J; Zitt, M; Kapp, KS; Fastner, G; Keil, F; Eisterer, W; Jäger, R; Offner, F; Gnant, M; Thaler, J; TAKO 05/ABCSG R-02 Trial Investigators.
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Strahlenther Onkol. 2011; 187(2):100-107 Doi: 10.1007/s00066-010-2182-6
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Kapp Karin S.; Schaberl-Moser Renate
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Purpose: In patients with locally advanced rectal cancer (LARC), preoperative chemoradiation is known to improve local control, and down-staging of the tumor serves as a surrogate for survival. Intensification of the systemic therapy may Lead to higher down-staging rates and, thus, enhance survival. This phase II study investigated the efficacy and safety of preoperative capecitabine and oxaliplatin in combination with radiotherapy. Patients and Methods: Patients with LARC of the mid and lower rectum, T3NxMO staged by MRI received radiotherapy (total dose 45 Gy) in combination with oral capecitabine (825 mg/m(2) twice a day on radiotherapy days; weeks 1-4) and oxaliplatin 50 mg/m2 intravenously (days 1, 8, 15, and 22). Efficacy was evaluated as rate of tumor down-categorization at the T level. Results: A total of 59 patients were enrolled (19 women, 40 men; median age of 61 years) and all were evaluable for efficacy and toxicity. Down-categorization at the T level was observed in 53% with pathological complete response in 6 patients (10%). Actual total radiotherapy, oxaliplatin and capecitabine doses received were 97%, 90%, and 93% of the protocol-specified preplanned doses, respectively. Grade 3/4 toxicity was observed in 15 patients (25%). The most frequent was diarrhea (12%). Conclusions: Preoperative chemoradiation with capecitabine and oxaliplatin is feasible in patients with MRI-proven cT3 LARC. The only clinically relevant toxicity was diarrhea. Overall, efficacy of the multimodality treatment was good, but not markedly exceeding that of 5-FU- or capecitabine-based chemoradiation approaches.
Find related publications in this database (using NLM MeSH Indexing): Adenocarcinoma - drug therapy; Administration, Oral -; Adult -; Aged -; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Combined Modality Therapy -; Deoxycytidine - administration & dosage; Dose-Response Relationship, Drug -; Drug Administration Schedule -; Feasibility Studies -; Female -; Fluorouracil - administration & dosage; Humans -; Infusions, Intravenous -; Male -; Middle Aged -; Neoadjuvant Therapy - methods; Neoplasm Invasiveness - pathology; Neoplasm Staging -; Organoplatinum Compounds - administration & dosage; Radiotherapy, Conformal -; Rectal Neoplasms - drug therapy; Treatment Outcome -
Find related publications in this database (Keywords): Rectal cancer; Chemoradiation; Capecitabine; Oxaliplatin